Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
Returns on capital
Maravai LifeSciences Holdings, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.6%
avg 4.0%
ROIC
-0.9%
avg 5.3%
ROA
-17.0%
avg -2.4%
Analysis
ROIC is currently the strongest return metric at -0.9% versus its period average of 5.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Bernd Brust | Chief Executive Officer & Director | USD 1.29M | 59 | 1.50M | 1.04% |
Rajesh J. Asorpota | Executive Vice President & Chief Financial Officer | USD 850.96K | 59 | — | — |
Christine Dolan | Executive Vice President & GM of Cygnus Technologies | USD 803.31K | 58 | 425.32K | 0.29% |
Kurt Oreshack | Executive Vice President, General Counsel & Secretary | USD 689.91K | 45 | 335.77K | 0.23% |
Robert Andrew Eckert | Chairman of the Board | USD 175K | 64 | — | — |
Kate E. Broderick | Executive Vice President | — | — | — | — |
Christopher Benoit | Executive Vice President & Advisor | — | — | — | — |
Chanfeng Zhao | Senior Vice President & Chief Scientific Officer | — | — | — | — |
Judith A. Solecki | Senior VP & Chief Human Resources Officer | — | — | — | — |
Debra Hart | Senior Director of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 9, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$368,544.16
Sells
2
$254,000.00
Net Transaction Value
+$114,544.16
Net buying
Most Active
ORESHACK KURT
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 10, 26Jun 10, 2026 | ORESHACK KURT Direct | Sell | $127.5K$127,500.00 |
| Jun 9, 26Jun 9, 2026 | ORESHACK KURT Direct | Sell | $126.5K$126,500.00 |
| Dec 8, 25Dec 8, 2025 | LUCIER GREGORY T Direct | Buy | $178.1K$178,097.76 |
| Dec 5, 25Dec 5, 2025 | LUCIER GREGORY T Direct | Buy | $190.4K$190,446.40 |
Summary
Insiders reported 2 buys worth $368,544.16 and 2 sells worth $254,000.00 over the last 12 months. That adds up to net buying of $114,544.16. ORESHACK KURT was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -40.5% | +8.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -40.5% over three years. Forward estimates point to Revenue at +8.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Maravai LifeSciences Holdings, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MRVI's management, answered from reported figures.
Who manages MRVI?
Maravai LifeSciences Holdings, Inc. (MRVI) lists 10 active executives. The top listed executive is Kate E. Broderick, Executive Vice President.
Are MRVI insiders buying or selling?
Recent insider activity shows net selling of $74.48M.
Continue the stock analysis
Jump to another research area for this company.